{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:45:53Z","timestamp":1791747953379,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National\u2002Natural\u2002Science\u2002Foundation\u2002of\u2002China","award":["82270197"],"award-info":[{"award-number":["82270197"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10495-026-02426-8","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:14:39Z","timestamp":1788786879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Activating a novel cell death pathway to target PI-resistant multiple myeloma and enhance immunogenic cell death"],"prefix":"10.1007","volume":"31","author":[{"given":"Xinyun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lexin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhuo","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2732-9354","authenticated-orcid":false,"given":"Bingzong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"1","key":"2426_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F et al (2024) Multiple myeloma. Nat Rev Dis Primers 10(1):45","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2426_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","volume":"13","author":"Y Yang","year":"2020","unstructured":"Yang Y et al (2020) Emerging agents and regimens for multiple myeloma. J Hematol Oncol 13(1):150","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2426_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1182\/blood.2019000722","volume":"134","author":"A Chari","year":"2019","unstructured":"Chari A et al (2019) Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 134(5):421\u2013431","journal-title":"Blood"},{"issue":"4","key":"2426_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S et al (2017) The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev 36(4):561\u2013584","journal-title":"Cancer Metastasis Rev"},{"key":"2426_CR5","doi-asserted-by":"publisher","first-page":"m3176","DOI":"10.1136\/bmj.m3176","volume":"370","author":"UA Shah","year":"2020","unstructured":"Shah UA, Mailankody S (2020) Emerging immunotherapies in multiple myeloma. BMJ 370:m3176","journal-title":"BMJ"},{"key":"2426_CR6","doi-asserted-by":"publisher","first-page":"609705","DOI":"10.3389\/fimmu.2020.609705","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang Y et al (2020) Research Status and Molecular Mechanism of the Traditional Chinese Medicine and Antitumor Therapy Combined Strategy Based on Tumor Microenvironment. Front Immunol 11:609705","journal-title":"Front Immunol"},{"issue":"6","key":"2426_CR7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/bph.14816","volume":"177","author":"SR Lin","year":"2020","unstructured":"Lin SR et al (2020) Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence. Br J Pharmacol 177(6):1409\u20131423","journal-title":"Br J Pharmacol"},{"issue":"12","key":"2426_CR8","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2174\/0929867013372094","volume":"8","author":"AK Mukherjee","year":"2001","unstructured":"Mukherjee AK et al (2001) Advances in cancer therapy with plant based natural products. Curr Med Chem 8(12):1467\u20131486","journal-title":"Curr Med Chem"},{"issue":"6","key":"2426_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2174\/1871520615666150304120643","volume":"15","author":"SM Nabavi","year":"2015","unstructured":"Nabavi SM et al (2015) Apigenin and Breast Cancers: From Chemistry to Medicine. Anticancer Agents Med Chem 15(6):728\u2013735","journal-title":"Anticancer Agents Med Chem"},{"key":"2426_CR10","doi-asserted-by":"crossref","unstructured":"Naeem A et al (2022) Natural Products as Anticancer Agents: Current Status and Future Perspectives. Molecules, 27(23)","DOI":"10.3390\/molecules27238367"},{"issue":"6","key":"2426_CR11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.biotechadv.2018.04.009","volume":"36","author":"A Mazumder","year":"2018","unstructured":"Mazumder A, Cerella C, Diederich M (2018) Natural scaffolds in anticancer therapy and precision medicine. Biotechnol Adv 36(6):1563\u20131585","journal-title":"Biotechnol Adv"},{"issue":"13","key":"2426_CR12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.phymed.2012.07.017","volume":"19","author":"H Liu","year":"2012","unstructured":"Liu H et al (2012) Chemical analysis of twelve lignans in the fruit of Schisandra sphenanthera by HPLC-PAD-MS. Phytomedicine 19(13):1234\u20131241","journal-title":"Phytomedicine"},{"issue":"5","key":"2426_CR13","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1111\/jcmm.16289","volume":"25","author":"X Xie","year":"2021","unstructured":"Xie X et al (2021) Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth. J Cell Mol Med 25(5):2645\u20132654","journal-title":"J Cell Mol Med"},{"issue":"1","key":"2426_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12964-024-01628-4","volume":"22","author":"T Li","year":"2024","unstructured":"Li T et al (2024) NCX1\/Ca(2+) promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NF\u03baB signaling pathway. Cell Commun Signal 22(1):258","journal-title":"Cell Commun Signal"},{"issue":"7","key":"2426_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrc1885","volume":"6","author":"S Grisendi","year":"2006","unstructured":"Grisendi S et al (2006) Nucleophosmin and cancer. Nat Rev Cancer 6(7):493\u2013505","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2426_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/2159-8290.CD-19-0672","volume":"10","author":"DA Erkes","year":"2020","unstructured":"Erkes DA et al (2020) Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis. Cancer Discov 10(2):254\u2013269","journal-title":"Cancer Discov"},{"issue":"7916","key":"2426_CR17","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41586-022-04825-8","volume":"606","author":"K Nozaki","year":"2022","unstructured":"Nozaki K et al (2022) Caspase-7 activates ASM to repair gasdermin and perforin pores. Nature 606(7916):960\u2013967","journal-title":"Nature"},{"issue":"6","key":"2426_CR18","first-page":"2962","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV (2008) Multiple myeloma Blood 111(6):2962\u20132972","journal-title":"Multiple myeloma Blood"},{"issue":"7","key":"2426_CR19","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","volume":"24","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA et al (2023) Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol 24(7):e293\u2013e311","journal-title":"Lancet Oncol"},{"issue":"1","key":"2426_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13046-022-02250-3","volume":"41","author":"I Oudaert","year":"2022","unstructured":"Oudaert I et al (2022) Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis. J Exp Clin Cancer Res 41(1):45","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2426_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ajh.23387","volume":"88","author":"TS Hawley","year":"2013","unstructured":"Hawley TS et al (2013) Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol 88(4):265\u2013272","journal-title":"Am J Hematol"},{"issue":"2","key":"2426_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41418-021-00862-4","volume":"29","author":"C Ren","year":"2022","unstructured":"Ren C et al (2022) Ubiquitination of NF-\u03baB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance. Cell Death Differ 29(2):381\u2013392","journal-title":"Cell Death Differ"},{"issue":"6","key":"2426_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/annonc\/mdh232","volume":"15","author":"LA deGraffenried","year":"2004","unstructured":"deGraffenried LA et al (2004) NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15(6):885\u2013890","journal-title":"Ann Oncol"},{"key":"2426_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ejmech.2019.07.041","volume":"180","author":"F Pojero","year":"2019","unstructured":"Pojero F et al (2019) Targeting multiple myeloma with natural polyphenols. Eur J Med Chem 180:465\u2013485","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2426_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-0186-y","volume":"5","author":"X Chen","year":"2020","unstructured":"Chen X et al (2020) Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification. Signal Transduct Target Ther 5(1):72","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"2426_CR26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-22-3631","volume":"83","author":"KR Sekhar","year":"2023","unstructured":"Sekhar KR, Freeman ML (2023) Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment. Cancer Res 83(10):1573\u20131580","journal-title":"Cancer Res"},{"issue":"10","key":"2426_CR27","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/leu.2009.124","volume":"23","author":"B Falini","year":"2009","unstructured":"Falini B et al (2009) Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 23(10):1731\u20131743","journal-title":"Leukemia"},{"key":"2426_CR28","doi-asserted-by":"crossref","unstructured":"Choudhury RH et al (2022) PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy. J Immunother Cancer, 10(2)","DOI":"10.1136\/jitc-2021-003526"},{"issue":"10","key":"2426_CR29","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41594-022-00842-3","volume":"29","author":"K Gonz\u00e1lez-Arzola","year":"2022","unstructured":"Gonz\u00e1lez-Arzola K et al (2022) Nucleus-translocated mitochondrial cytochrome c liberates nucleophosmin-sequestered ARF tumor suppressor by changing nucleolar liquid-liquid phase separation. Nat Struct Mol Biol 29(10):1024\u20131036","journal-title":"Nat Struct Mol Biol"},{"issue":"9","key":"2426_CR30","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.7150\/thno.71086","volume":"12","author":"Z Rao","year":"2022","unstructured":"Rao Z et al (2022) Pyroptosis in inflammatory diseases and cancer. Theranostics 12(9):4310\u20134329","journal-title":"Theranostics"},{"issue":"9","key":"2426_CR31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.tcb.2017.05.005","volume":"27","author":"SB Kovacs","year":"2017","unstructured":"Kovacs SB, Miao EA (2017) Gasdermins: Effectors of Pyroptosis. Trends Cell Biol 27(9):673\u2013684","journal-title":"Trends Cell Biol"},{"issue":"3","key":"2426_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.immuni.2020.02.012","volume":"52","author":"KC Barnett","year":"2020","unstructured":"Barnett KC, Ting JP (2020) Mitochondrial GSDMD Pores DAMPen Pyroptosis. Immunity 52(3):424\u2013426","journal-title":"Immunity"},{"issue":"1","key":"2426_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13046-021-01959-x","volume":"40","author":"Y Tan","year":"2021","unstructured":"Tan Y et al (2021) Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res 40(1):153","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"2426_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.tim.2021.11.011","volume":"30","author":"S Verdonck","year":"2022","unstructured":"Verdonck S et al (2022) Viral manipulation of host cell necroptosis and pyroptosis. Trends Microbiol 30(6):593\u2013605","journal-title":"Trends Microbiol"},{"issue":"8","key":"2426_CR35","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1002\/ctm2.492","volume":"11","author":"T Du","year":"2021","unstructured":"Du T et al (2021) Pyroptosis, metabolism, and tumor immune microenvironment. Clin Transl Med 11(8):e492","journal-title":"Clin Transl Med"},{"issue":"1","key":"2426_CR36","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13046-021-02065-8","volume":"40","author":"R Loveless","year":"2021","unstructured":"Loveless R, Bloomquist R, Teng Y (2021) Pyroptosis at the forefront of anticancer immunity. J Exp Clin Cancer Res 40(1):264","journal-title":"J Exp Clin Cancer Res"},{"issue":"7799","key":"2426_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","volume":"579","author":"Z Zhang","year":"2020","unstructured":"Zhang Z et al (2020) Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579(7799):415\u2013420","journal-title":"Nature"},{"issue":"7799","key":"2426_CR38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-020-2079-1","volume":"579","author":"Q Wang","year":"2020","unstructured":"Wang Q et al (2020) A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature 579(7799):421\u2013426","journal-title":"Nature"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02426-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:48:49Z","timestamp":1791744529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02426-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02426-8","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiments were approved by the Ethics Committee of Soochow University (Permit Number: SUDA202205A0167). All MM patient samples were collected from the Second Affiliated Hospital of Soochow University after obtaining permission from the Ethics Committee of the Second Affiliated Hospital of Soochow University (Permit Number: JD-LK-2019-068-05). Informed written consent was obtained from each subject or guardian. This study was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have consented to the publication of this manuscript. This manuscript does not contain data from any individual person; therefore, additional consent for publication was not required.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"225"}}